Calvet X, García N, Campo R, Brullet E, Comet R, Navarro M
Internal Medicine department, and Digestive Endoscopy Unit (SDI), Consorci Hospitalari del Parc Taulí, Sabadell (Barcelona), Spain.
Am J Gastroenterol. 1998 Jun;93(6):932-4. doi: 10.1111/j.1572-0241.1998.00281.x.
We sought to compare a 2-day quadruple therapy with a 14-day triple therapy in the treatment of Helicobacter pylori infection.
Eighty-one consecutive patients with an endoscopically diagnosed peptic ulcer and demonstrated infection by H. pylori were included in the study. Patients were randomized to receive omeprazole 40 mg b.i.d., amoxicillin 2.5 g once daily, metronidazole 500 mg t.i.d., and bismuth subcitrate 360 mg t.i.d. for 2 days, followed by omeprazole 20 mg once daily for 6 additional days (Group 1) or a 14-day course of omeprazole 20 mg b.i.d., amoxicillin 1 g t.i.d., and metronidazole 500 mg t.i.d. (Group 2). Eradication was evaluated by antral biopsy and rapid urease test at 2 months after therapy and by C13-urea breath test after a year.
Two patients were lost to follow-up at 2 months. Intention-to-treat analysis showed that H. pylori infection was cured in 29 of 42 patients (69%; 95% CI: 53-82%) in Group 1 versus 36 of 39 (92%; 95% CI: 78-98%) of patients in Group 2 (p = 0.009). Per-protocol analysis showed a cure rate of 71% (95% CI: 55-84%) (29/41 patients) and 95% (95% CI: 81-99%) (36/38 patients), respectively (p = 0.007). Fifty-five of 65 cured patients returned 1 year after treatment (26 in Group 1, 29 in Group 2). All but one in Group 2 remained cured. There were no significant differences in compliance (88% in Group 1 versus 92% in Group 2) or in the presence of side effects (27%; 95% CI: 15-43% versus 41%; 95% CI: 26-58%; ns).
Two-day quadruple therapy is significantly less effective than 2-wk triple treatment.
我们试图比较2天四联疗法与14天三联疗法治疗幽门螺杆菌感染的效果。
81例经内镜诊断为消化性溃疡且证实感染幽门螺杆菌的连续患者纳入本研究。患者被随机分为两组,一组接受奥美拉唑40毫克每日两次、阿莫西林2.5克每日一次、甲硝唑500毫克每日三次、枸橼酸铋钾360毫克每日三次,共2天,随后奥美拉唑20毫克每日一次,再持续6天(第1组);另一组接受奥美拉唑20毫克每日两次、阿莫西林1克每日三次、甲硝唑500毫克每日三次,共14天(第2组)。治疗后2个月通过胃窦活检和快速尿素酶试验评估根除情况,1年后通过C13尿素呼气试验评估。
2个月时2例患者失访。意向性分析显示,第1组42例患者中有29例(69%;95%可信区间:53 - 82%)幽门螺杆菌感染治愈,第2组39例患者中有36例(92%;95%可信区间:78 - 98%)治愈(p = 0.009)。符合方案分析显示治愈率分别为71%(95%可信区间:55 - 84%)(41例患者中的29例)和95%(95%可信区间:81 - 99%)(38例患者中的36例)(p = 0.007)。65例治愈患者中有55例在治疗1年后回访(第1组26例,第2组29例)。第2组除1例患者外其余均保持治愈状态。两组在依从性(第1组88%,第2组92%)或副作用发生情况(27%;95%可信区间:15 - 43%对41%;95%可信区间:26 - 58%;无显著性差异)方面均无显著差异。
2天四联疗法的疗效显著低于2周三联疗法。